Triple Negative Breast Cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients >=18 years of age with final pathological diagnosis of triple-negative breast cancer; 2.Breast enhanced MRI was performed one month before surgery. MRI included high B-value DWI sequence, DCE-MRI sequence and T2 sequence data acquisition; 3.Fresh pathological tissue was obtained by puncture; 4.MRI followed by immunotherapy (pabolizumab vs. Attilizumab regimen);
Exclusion criteria
Exclusion criteria: 1.The lesion could not be clearly identified on breast MRI; 2.Clinical features are missing or incomplete; 3.Received any antitumor therapy prior to MRI; 4.Present or co-present with other tumors;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of immune microenvironment characteristics;Evaluation of immunotherapy response; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of immune-related side effects; | — |
Countries
China
Contacts
Jiaxing Hospital of Traditional Chinese Medicine